CONJUPRI
PeakSMlevamlodipine
NDAORALTABLET
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
CONJUPRI (levamlodipine) is (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. First approved in 2019.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONJUPRI (levamlodipine) is the pharmacologically active S-enantiomer of amlodipine, a calcium channel antagonist used to treat hypertension and angina by reducing peripheral vascular resistance. It works by selectively inhibiting calcium ion influx into vascular smooth muscle cells, with a gradual onset of action due to slow receptor binding kinetics. Levamlodipine is the therapeutically active isomer of the racemic amlodipine mixture, offering potential for optimized efficacy and safety profiles.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%) indicating a stable but competitive market environment requiring strong differentiation and field execution.
Mechanism of Action
(calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects
Started May 2018
36 enrolled
Hypertension
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.